Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016 | Original Article

St Gallen molecular subtypes in feline mammary carcinoma and paired metastases—disease progression and clinical implications from a 3-year follow-up study

Authors: M. Soares, J. Correia, M. C. Peleteiro, F. Ferreira

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

Considering that scarce data are available on disease progression of feline mammary carcinoma (FMC), this study aimed to analyze the clinical, pathological, and immunophenotypic features collected from 61 queens with FMC and to compare the concordance ratios of the expression levels of five molecular markers (ER, PR, fHER2, CK5/6, and Ki-67) between primary tumors (PT) and metastatic lesions. The results showed that cats with luminal A mammary carcinomas (MC) had higher overall survival (924.6 days, p = 0.001) and longer disease-free period (385.4 days, p = 0.005) compared to the ones with other MC subtypes. In fact, queens with triple negative/basal-like MC showed the lowest survival (mean 156.2 days) and the shortest disease-free survival (mean 28 days) among the molecular subtypes of MC. The lung was the organ most frequently affected by metastases, and animals with lung and/or pleural metastases were more likely to display metastases at three or more locations (p = 0.039). A large heterogeneity in protein expression levels was found between PT and paired metastases, with both estrogen and progesterone receptors more likely to be downregulated in metastases. Paired metastases frequently had higher Ki-67 index than PT, whereas fHER2 overexpression was seen in 46 samples (30 %) and CK5/6 expression was found in 50.7 % of metastases (36/71). Results also revealed that disease progression leads to a high percentage of triple negative/basal-like metastases (9/23; 39.1 %) associated with the absence of luminal A subtype in distant metastases (0/23). This study highlights the prognostic importance of immunophenotyping of MC in cats, although the modified protein expression identified in metastases contributes to justify why possible targeted therapies may fail in some animals with metastatic disease. Altogether, the results obtained also demonstrate that FMC can be used as a model to study human breast cancer.
Appendix
Available only for authorised users
Literature
1.
Sorenmo KU, Worley DR, Goldschmidt MH. Tumors of the mammary gland. In: Withrow, MacEwen’s, editors. Small animal clinical oncology. 5th ed. Missouri: Saunders Elsevier; 2013. p. 538–56.CrossRef
2.
Zappulli V, Rasotto R, Caliari D, Mainenti M, Peña L, Goldschmidt MH, et al. Prognostic evaluation of feline mammary carcinomas: a review of the literature. Vet Pathol. 2015;52:46–60.CrossRefPubMed
3.
Weigelt B, Glas AM, Wessels LFA, Witteveen AT, Peterse JL, van’t Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. PNAS. 2003;100:15901–5.CrossRefPubMedPubMedCentral
4.
Montel V, Huang TY, Mose E, Pestonjamasp K, Tarin D. Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model. Am J Pathol. 2005;166:1565–79.CrossRefPubMedPubMedCentral
5.
Suzuki M, Tarin D. Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications. Mol Oncol. 2007;1:172–80.CrossRefPubMed
6.
Chan A, Morey A, Brown B, Hastrich D, Willsher P, Ingram D. A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. BMC Cancer. 2012;12:555.CrossRefPubMedPubMedCentral
7.
Montel V, Mose ES, Tarin D. Tumor-stromal interactions reciprocally modulate gene expression patterns during carcinogenesis and metastasis. Int J Cancer. 2006;119:251–63.CrossRefPubMed
8.
Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of change in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010;21:1254–61.CrossRefPubMed
9.
Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277–89.CrossRefPubMed
10.
Raica M, Cîmpean AM, Ceauşu RA, Fulga V, Nica C, Rudico L, et al. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both? Anticancer Res. 2014;34:1435–40.PubMed
11.
Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30:593–9.CrossRefPubMed
12.
Falck AK, Fernö M, Bendahl PO, Rydén L. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases—aspects on distribution and prognosis for patients with luminal A tumours : results from a prospective randomised trial. BMC Cancer. 2013;13:558.CrossRefPubMedPubMedCentral
13.
Yao ZX, Lu LJ, Wang RJ, Jin LB, Liu SC, Li HY, et al. Discordance and clinical significance of ER, PR and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol. 2014;31:798.CrossRefPubMed
14.
de las Mulas JM, van Niel M, Millán Y, Blankenstein MA, van Mil F, Misdorp W. Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domest Anim Endocrinol. 2000;18:111–25.CrossRefPubMed
15.
Millanta F, Calandrella M, Citi S, Della Santa D, Poli A. Overexpression of HER-2 in feline invasive mammary carcinomas: na immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol. 2005;42:30–4.CrossRefPubMed
16.
Millanta F, Calandrella M, Vannozzi I, Poli A. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Vet Rec. 2006;158:821–4.CrossRefPubMed
17.
Rasotto R, Caliari D, Castagnaro M, Zanetti R, Zappulli V. An immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp Pathol. 2011;144:170–9.CrossRefPubMed
18.
Seixas F, Palmeira C, Pires MA, Bento MJ, Lopes C. Grade is an independent prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis. Vet J. 2011;187:65–71.CrossRefPubMed
19.
Peñafiel-Verdu C, Buendia AJ, Navarro JA, Ramirez GA, Vilafranca M, Altimira J, et al. Reduced expression of E-cadherin and β-catenin and high expression of basal cytokeratins in feline mammary carcinomas with regional metastasis. Vet Pathol. 2012;49:979–87.CrossRefPubMed
20.
Soares M, Correia J, Rodrigues P, Simões M, de Matos A, Ferreira F. Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of immunohistochemistry (IHC) and in situ hybridization (ISH) techniques. Microscopy Microanalysis. 2013;19:1–7.
21.
Maniscalco L, Iussich S, Martin de las Mulas J, Millán Y, Biolatti B, Sasaki N, et al. Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours. Vet J. 2012;191(1):65–71.CrossRefPubMed
22.
Brunetti B, Asproni P, Beha G, Muscatello LV, Millanta F, Poli A, et al. Molecular phenotype in mammary tumours of queens: correlation between primary tumour and lymph node metastasis. J Comp Pathol. 2013;148:206–13.CrossRefPubMed
23.
Soares M, Correia J, Murta A, Ferreira F. Immunophenotyping of primary and metastatic lesions in feline mammary tumors—are they equal? Microscopy Microanalysis. 2013;19 Suppl 4:19–20.CrossRef
24.
Beha G, Muscatello LV, Brunetti B, Asproni P, Millanta F, Poli A, et al. Molecular phenotype of primary mammary tumors and distant metastases in female dogs and cats. J Comp Pathol. 2014;150:194–7.CrossRefPubMed
25.
Elston CW, Ellis IO. Assessment of histological grade. In: Rosen’s breast pathology. Philadelphia: Lippincott-Raven; 1998. p. 365–82.
26.
Misdorp W. Tumors of the mammary gland. In: Tumors in Domestic Animals. Fourth Ed. Meuten DJ editor, Iowa: 2002. pp. 575–606.
27.
Mills SW, Musil KM, Davies JL, Hendrick S, Duncan C, Jackson ML, Kidney B, Philibert H, Wobeser BK, Simko E. Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis. Vet Pathol. 2014; 1–12.
28.
Harvey JM, Clark GM, Osborne CK, Allred C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.PubMed
29.
Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh LD, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545–54.CrossRefPubMed
30.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4014.CrossRefPubMed
31.
De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, et al. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res. 2005;65:907–12.PubMed
32.
Ordás J, Millán Y, Dios R, Reymundo C, de las Mula JM. Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer. 2007;7:179.CrossRefPubMedPubMedCentral
33.
Santos S, Baptista C, Abreu RMV, Bastos E, Amorim I, Gut IG, et al. ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer. Plos One. 2013;8, e83673.CrossRefPubMedPubMedCentral
34.
Soares M, Ribeiro R, Carvalho S, Peleteiro M, Correia J, Ferreira F. Ki-67 as a Prognostic Factor in Feline Mammary carcinoma: what is the optimal cutoff value? Veterinary Pathology. 2015.
35.
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebnart M, Thürlimann B, et al. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol. 2013;24:2206–23.CrossRefPubMedPubMedCentral
36.
Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. 2014;232:23–31.CrossRefPubMed
37.
Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20:1499–504.CrossRefPubMedPubMedCentral
38.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.CrossRefPubMed
39.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134:48–72.
40.
Kwast ABG, Voogd AC, Menke-Pluijmers MBE, Linn SC, Sonke GS, Kiemeney LA, et al. Prognostic factors for survival in metastatic breast cancer by hormone receptor status. Breast Cancer Res Treatment. 2014;145:503–11.CrossRef
41.
Yu K, Di G, Wu J, Lu J, Shen K, Liu G, et al. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment. J Cancer Res Clin Oncol. 2008;134:1347–54.CrossRefPubMed
42.
Ng CH, Pathy NB, Taib NA, Mun KS, Rhodes A, Yip CG. The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact. Asian Pacific J Cancer Prev. 2012;13:1111–3.CrossRef
43.
Macfarlane R, Seal M, Speers C, Woods R, Masoudi H, Aparicio S, et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist. 2012;17:172–8.CrossRefPubMedPubMedCentral
44.
Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–71.CrossRefPubMed
45.
Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 2010;36:206–15.CrossRefPubMed
46.
Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and Ck5 in early and late relapsing breast cancer—reduced CK 5 expression in metastases. Breast Cancer: Basic Clin Res. 2013;7:23–34.
47.
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.CrossRefPubMed
48.
Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by panel of four biomarkers using immunohistochemistry. Breast. 2012;21:50–7.CrossRefPubMed
49.
Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol. 2013;66:512–6.CrossRefPubMed
50.
Maniscalco L, Millán Y, Iussich S, Denina M, Sánchez-Céspedes R, Gattino F, et al. Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas. BMC Vet Res. 2013;9:80.CrossRefPubMedPubMedCentral
51.
Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, Kiupel M. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. BMC Cancer. 2013;13:403.CrossRefPubMedPubMedCentral
Metadata
Title
St Gallen molecular subtypes in feline mammary carcinoma and paired metastases—disease progression and clinical implications from a 3-year follow-up study
Authors
M. Soares
J. Correia
M. C. Peleteiro
F. Ferreira
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4251-z

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Research Article

S100A4 participates in epithelial-mesenchymal transition in breast cancer via targeting MMP2

Original Article

Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer

Original Article

Elevated OCT1 participates in colon tumorigenesis and independently predicts poor prognoses of colorectal cancer patients

Original Article

Genetic variants in the ITGB6 gene is associated with the risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy

Original Article

Synthetic Tet-inducible small hairpin RNAs targeting hTERT or Bcl-2 inhibit malignant phenotypes of bladder cancer T24 and 5637 cells

Original Article

Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits